Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00662675 · ClinicalTrials.gov registry record · Phase 3
A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency
A Phase 3 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
NCT00662675 is a Phase 3 study that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 40 participants.
The verdict
NCT00662675, a Phase 3 study, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effectiveness and safety of oral pancrelipase MT in the treatment of adult and pediatric/adolescent cystic fibrosis (CF) patients with clinical symptoms of exocrine pancreatic insufficiency (EPI).
Interventions
- DRUG Pancrease MT 10.5, or MT 21
- DRUG Placebo for Pancrease MT 10.5 or MT 21
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-08 |
| Est. Completion | 2009-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00662675
The ClinicalTrials.gov registry entry for NCT00662675 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pancrease MT 10.5, or MT 21 is the first listed.
NCT00662675 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00662675 about?
NCT00662675 is a clinical study titled "A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency". The purpose of this study is to assess the effectiveness and safety of oral pancrelipase MT in the treatment of adult and pediatric/adolescent cystic fibrosis (CF) patients with clinical symptoms of exocrine pancreatic insufficiency (EPI).
What is the current status of trial NCT00662675?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2008-08. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00662675?
The interventions under investigation include: Pancrease MT 10.5, or MT 21 (DRUG), Placebo for Pancrease MT 10.5 or MT 21 (DRUG).
Who is sponsoring clinical trial NCT00662675?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.